La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Allogene Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Allogene Therapeutics..

Allogene Therapeutics (NASDAQ:ALLO) Azioni, Catena delle Opzioni

Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics Inc

ALLON THERAPEUTICS INC by Allon Therapeutics Inc.

AlloVir Inc

Allot Ltd

Benchmark analyst Fawne Jiang maintains H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) with a Buy and lowers the price target from $53 to $48.

News

Price Target

Analyst Ratings

HTHT

Benchmark Maintains Buy on H World Group, Lowers Price Target to $48

Shares of&nbsp;CrowdStrike Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) dropped by 6.14% in pre-market trading on Wednesday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>. This decline followed a weaker-than-anticipated earnings forecast for the upcoming quarter, despite the company surpassing Wall Street estimates for the third quarter.
What Happened: CrowdStrike projected adjusted earnings of $0.84 to $0.86 per share for the fiscal fourth quarter, missing Wall Street&#8217;s expectation of $$0.86 cents per share. Despite this, the cybersecurity firm reported record revenue of $1.01 billion in the third quarter, exceeding the consensus estimate of $982.36 million. Adjusted earnings stood at $0.93 per share, surpassing analyst predictions of $0.81 per share.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42154817/crypto-analyst-sees-shiba-inu-surging-more-than-2000-in-coming-rally?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto Analyst Sees Shiba Inu Surging More Than 2,000% In Coming Rally</a>
The company&#8217;s recent performance follows a problematic <a href="https://www.benzinga.com/news/24/07/39870313/microsoft-crowdstrike-issue-caused-largest-it-outage-in-history-showing-how-much-we-depend-on-a-hand">software update in July </a>that caused global computer crashes. Investors have been closely monitoring&nbsp;CrowdStrike&nbsp;for signs of recovery since the incident. While the third-quarter results were strong, the cautious outlook for the upcoming quarter has tempered investor enthusiasm.
Meanwhile, post the earnings, Needham &amp; Company upgraded the price target from $360 to $420 while HSBC has downgraded to $347, as per <a href="https://pro.benzinga.com">Benzinga Pro</a> data.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/CRWD/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27072909/Screenshot-2024-11-27-at-5.59.02%E2%80%AFPM-1024x394.png" alt="" class="wp-image-667216" /></a></figure>
Why It Matters: The recent earnings report highlights&nbsp;CrowdStrike&#8217;s&nbsp;ability to recover from the July software update fallout, which had significant global repercussions. The company has consistently <a href="https://www.benzinga.com/news/earnings/24/11/42202105/crowdstrike-beats-q3-earnings-revenue-estimates-cybersecurity-company-highlights-incredible-success-retaining-customers-following-it-outage">exceeded analyst estimates </a>since its public debut in 2019, showcasing resilience and strong customer retention.
Despite the technical challenges earlier in the year, CrowdStrike has<a href="https://www.benzinga.com/news/earnings/24/11/42209469/crowdstrike-stocks-technical-analysis-shows-bullish-trend-as-it-navigates-july-fallout-to-deliver-record-q3-revenue-heres-more"> demonstrated a bullish trend</a>. Despite falling in premarket trading on Wednesday, at $344 a piece, CrowdStrike's stock is above its 20, 50, and 200-day simple moving averages, suggesting a largely bullish trend.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42206056/bitcoin-ethereum-dogecoin-tumble-as-diamond-hands-lock-in-gains-analyst-anticipates-strong-buyback-pressure-to-follow-sell-pressure?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Tumble As &#8216;Diamond Hands&#8217; Lock In Gains: Top Analyst Anticipates BTC Rebound</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

General

CRWD

CrowdStrike Shares Fall 6% Despite Beating Q3 Estimates: What's Going On?

Grant Cardone is getting vocal about housing. The real estate mogul and entrepreneur took to Twitter with strong words on the topic. &#8220;The average rate on a 30-year fixed mortgage is 6.84% this week,&#8221; <a href="https://x.com/GrantCardone/status/1859961992460816613">he tweeted,</a> citing Freddie Mac data. &#8220;The 7th weekly increase over the past eight weeks. If this continues, homeownership is OVER in America.&#8221;
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>
Bold claim? Yeah, but Cardone's not wrong about rates climbing fast. Mortgage rates have been creeping up for months. They're at levels not seen in over two decades. For context, the 30-year fixed mortgage rate averaged just 3% in 2021.. Today, it's more than double that. That spike is slamming potential homebuyers. Monthly payments are skyrocketing and dreams of owning a home feel like a pipe dream.
Cardone is known for his real estate empire and no-nonsense business advice. He has a long history of talking about housing. He's built his career around multifamily real estate. He also owns thousands of apartment units across the U.S. and has never been shy about saying <a href="https://www.benzinga.com/markets/24/11/42146196/homeownership-vs-renting-why-grant-cardone-thinks-the-american-dream-is-a-terrible-investment">homeownership isn't for everyone.</a> But this time, it's different. He's not just talking about the challenges of owning a home. He's saying rising rates could kill the American dream altogether.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
He didn't stop there. &#8220;America should have the best housing &amp; the lowest interest rates in the world,&#8221; he added. A big statement, but Cardone has a point. Higher rates don't just hurt buyers. They ripple through the entire economy. Housing is a massive driver of growth. When people can't buy, homebuilders stop building and industries like construction and home goods take a hit.
Cardone's tweet reflects the frustration of many. Rising rates are making housing <a href="https://www.benzinga.com/real-estate/24/10/41166593/grant-cardone-dispels-the-american-dream-of-homeownership-citing-mortgage-payments-as-double-the-ren">unaffordable for millions. </a>In 2021, the average 30-year fixed mortgage rate was 3%. A $300,000 mortgage at 3% costs around $1,265 a month. At today's rates? That same loan will set you back over $2,000. That's not chump change.
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
This isn't just about numbers, either. For decades, homeownership has been a symbol of stability and success in America. But now, it's slipping further out of reach. Younger generations are especially hurting. Millennials and Gen Z, already burdened by student loans and rising living costs, are being hit the hardest.
The solution? That's up for debate. Some experts say the Federal Reserve needs to ease up on rate hikes. Others argue for more affordable housing options. Cardone's take? He didn't spell it out this time, but knowing him, he'd probably say it's time to think bigger and <a href="https://www.facebook.com/grantcardonefan/videos/invest-in-assets-that-produce-cash-flow/461800760050933/">focus on cash flow</a>. That could mean renting, investing or finding new ways to build wealth.
One thing's clear: If rates keep climbing, the housing market will keep feeling the heat. And for many, homeownership might be &#8220;OVER,&#8221; just like Cardone said.
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Real Estate

Freddie Mac Reports 6.84% Mortgage Rate As Grant Cardone Warns Of Homeownership Crisis

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dip to $93,000 can be attributed to pressure from a combination of macroeconomic shifts, technical signals and on-chain trends, according to the latest note by 10x Research.
Despite this, the long-term outlook for 2025 appears optimistic, aligning with Bitcoin's historical cycles and broader economic trends, the analysts report.
The impact of rate cuts 
<ol>
<li></li>
</ol>
One of the primary drivers of Bitcoin's decline is the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Federal Reserve's cautious approach</a> to monetary easing.
"The FOMC minutes hint at a pause in monetary easing," the report notes, highlighting how this shift removes a critical tailwind that has historically supported Bitcoin's growth. 
Without the added boost from loose fiscal policies, Bitcoin has lost some of its upward momentum, exposing vulnerabilities in its price action.
Global liquidity taps start closing
Another factor impacting Bitcoin is its close correlation with <a href="https://www.benzinga.com/24/11/42170458/crude-oil-down-2-chicago-fed-national-activity-index-falls-in-october">global money supply changes</a>.
The report points out that "over the past 12 months, a clear correlation has emerged, with changes in money supply leading Bitcoin's movements by approximately ten weeks." 
This lagging effect has played out recently, as Bitcoin peaked in November following earlier monetary policy adjustments. 
However, with the pace of monetary expansion slowing, Bitcoin has struggled to maintain its previous trajectory.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42198909/trump-linked-crypto-platform-world-liberty-financial-appoints-justin-sun-as-advisor-after-30-million-investment">Trump-Linked Crypto Platform World Liberty Financial Appoints Justin Sun As Advisor After $30 Million Investment</a>
Technical indicators
<a href="https://www.benzinga.com/money/what-you-need-to-know-about-technical-analysis">Technical indicators</a> also reveal why Bitcoin's price has faltered.
According to the report, Bitcoin "confirmed bearish daily reversal signals in play, with weekly signals likely to follow," suggesting a potential correction from overbought levels. 
Analysts have identified critical support levels at $89,000 and $75,000, which will be key in determining whether Bitcoin can stabilize and regain momentum.
On-chain metrics offer additional context. 
The realized profit-loss ratio and changes in long-term holder positions have signaled increased selling pressure from experienced investors. 
The report notes, "A meaningful signal only emerges when this ratio reverses lower—indicating that longer-term holders are slowing their profitable coin sales."
This suggests that selling momentum could ease in the near future, paving the way for consolidation and eventual recovery.
What&#8217;s Next
Looking ahead, the report offers a cautiously optimistic view. 
While December has historically been a bullish month for Bitcoin, the broader outlook for 2025 remains the real focus. 
The report reinforces this sentiment, stating, "This pattern has consistently played out during Bitcoin&#8217;s short history, pointing to a continued bullish outlook for 2025." 
With cyclical trends and potential macroeconomic shifts aligning, Bitcoin may be poised for another strong performance in <a href="https://www.benzinga.com/money/bitcoin-price-prediction">the years ahead</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42196910/pantera-bitcoin-fund-hits-1000x-return-predicts-btc-at-740000-by-2028">Pantera Bitcoin Fund Hits 1,000X Return, Predicts BTC At $740,000 By 2028</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin At $93,000—Crash Or Pause? 'Bullish Outlook For 2025,' Says 10x Research

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

ARWR

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $295 to $325.

ADSK

Rosenblatt Maintains Buy on Autodesk, Raises Price Target to $325

AMBA: 29% &#x7C; <a href="https://www.benzinga.com//node/42201842">Ambarella shares are trading higher after the company reported a year-over-year increase in Q3 revenue results.</a>
&nbsp;
TRNR: 86% &#x7C; <a href="https://www.benzinga.com//node/42210976">Interactive Strength Receives Letter Confirming Demonstrated Compliance With Nasdaq Listing Rule, Which Successfully Concludes Hearings Panel Appeal Process That Began In May</a>
&nbsp;
DELL: -13% &#x7C; <a href="https://www.benzinga.com//node/42201722">Dell Technologies shares are trading lower following a Q3 revenue miss.</a>

Movers

Trading Ideas

AMBA

DELL

TRNR

Market-Moving News for November 27th

Benchmark analyst Christopher Kuhn maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Buy and raises the price target from $32 to $34.

SNDR

Benchmark Maintains Buy on Schneider National, Raises Price Target to $34

Legendary investor&nbsp;Warren Buffett&nbsp;has a piece of critical advice for parents that he believes they should follow, regardless of their wealth status.
What Happened: In a recent letter, the Berkshire Hathaway CEO advised parents to not just write their will but also discuss it with their children.
"Be sure each child understands both the logic for your decisions and the responsibilities they will encounter upon your death," the Oracle of Omaha said.
This, Buffett says, essentially ensures that there is clarity about the inheritance between parents and their children, reducing the chances of disputes. This is especially important when parents are no longer there to resolve differences over matters such as these.
"If any have questions or suggestions, listen carefully and adopt those found sensible. You don't want your children asking ‘Why?' in respect to
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci: Trump Win Is &#8216;The Greatest Political Comeback In US History'</a>
Buffett&#8217;s letter also recounted instances where families were torn apart due to unclear testamentary directives.
He encouraged parents to invite their adult children to discuss the will, ensuring transparency and understanding.
Why It Matters: This advice from Buffett aligns with his recent actions, including&nbsp;<a href="https://www.benzinga.com/news/24/11/42177867/warren-buffett-announces-new-charitable-gifts-updates-plans-for-150b-fortune-billionaire-wants-to-help-others-given-a-very-short-straw-at-birth">announcing new charitable donations</a>&nbsp;and updates to his $150 billion fortune.
Buffett has been converting Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) shares to make these donations, emphasizing his commitment to philanthropy.
Buffett&#8217;s family dynamics also reflect his philosophy. His daughter-in-law, Mary Buffett, once thought she would receive &#8220;free candy&#8221; upon marrying his son, but learned there was no such thing with Warren, highlighting his emphasis on self-reliance and integrity.
This perspective is consistent with his hiring philosophy, where he values&nbsp;<a href="https://www.benzinga.com/startups/24/11/41976499/warren-buffett-shares-three-key-traits-to-look-for-when-hiring-says-that-without-integrity-the-other-two-will-kill-you">integrity above all</a>&nbsp;other traits.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42155884/economist-slams-doges-simplistic-approach-to-government-spending-questions-super-bowl-ad-criticism?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Economist Slams DOGE: Tells Elon Musk-Led Initiative To &#8216;Do Your Legal Job Well&#8217; Amid Super Bowl Ad Spending Clash</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Personal Finance

Warren Buffett Says Parents Should Do This One Thing Before They Die, Whether They Are Rich Or Not

Guidance

Symbotic Cuts Q1'FY25 Revenue Outlook From $495M - $515M To $480M - $500M (Est $503.579M)

Rosenblatt analyst Catharine Trebnick maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and maintains $385 price target.

Rosenblatt Maintains Buy on CrowdStrike Holdings, Maintains $385 Price Target

As a result, gross profit, income (loss) before income tax, net income (loss) and adjusted EBITDA1 were also impacted. The company estimates the total impact of correcting these errors will be to lower system revenue, system gross profit, income (loss) before income tax, and adjusted EBITDA by $30 million to $40 million for fiscal year 2024 compared to the financial results released on November 18, 2024.

Symbotic Says Identified Errors In Its Revenue Recognition Related To Cost Overruns

Contracts

CAMT

Camtek Secures $50M In Pre-Launch Orders For New Hawk Product Ahead Of February 2025 Debut

CDRO

Codere Online Luxembourg Reports Q3 Revenues Of €49.2M Up From €41M YoY; Total Cash Position Of €44.0M As Of September 30

Symbotic Reports Delay In Filing Annual Report On Form 10-K; Says It Requires Additional Time To Complete Assessment Of Financial Impacts Of Correcting An Error Related To System Revenue Recognition

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Electra Battery Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>) with a Buy and lowers the price target from $1.4 to $1.3.

ELBM

HC Wainwright & Co. Maintains Buy on Electra Battery Materials, Lowers Price Target to $1.3

LASE

Laser Photonics Says Pre-Orders Are Open For Its Soon To Be Launched CTIR-3060

Denison Mines Partners With Cosa Resources To Form Joint Ventures For Uranium Exploration In Athabasca Basin

As an Amazon Web Services (AWS) partner, Beamr brings its GPU-accelerated video solutions to the curated digital storefront, enabling customers to easily discover, purchase, and deploy offerings from trusted AWS partners.
Furthermore, Beamr Cloud is expected to become a member of the AWS ISV Accelerate program, a co-sell program for independent software vendors (ISVs) that provide software solutions that are integrated with AWS.

Beamr Imaging Says Beamr Cloud Video Service Will Be Available On AWS Marketplace Starting December 1, 2024

UBS analyst Michael Lasser upgrades Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) from Neutral to Buy and raises the price target from $225 to $260.

Upgrades

UBS Upgrades Dick's Sporting Goods to Buy, Raises Price Target to $260

William Blair analyst Sami Corwin has maintained their bullish stance on ALLO stock, giving a Buy rating yesterday. Sami Corwin's rating is based o...

Promising Efficacy and Strategic Advancements Propel Allogene Therapeutics to a Buy Rating

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a price ...

RBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cartesian Therapeutics (RNAC – Research Report), Allogene Therape...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)

Oppenheimer analyst Matthew Biegler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of $10.0...

Oppenheimer Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Allogene Therapeutics (ALLO – Research Report). The associated price ta...

Promising Clinical Data and Strong Financial Position Reinforce Buy Rating for Allogene Therapeutics

In a report released today, Reni Benjamin from JMP Securities maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report). The compa...

JMP Securities Remains a Hold on Allogene Therapeutics (ALLO)

William Blair analyst Sami Corwin has reiterated their bullish stance on ALLO stock, giving a Buy rating on November 11. Sami Corwin has given his ...

Strategic Resource Reallocation and Growth Focus Underpin Buy Rating for Allogene Therapeutics

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of $9.00. T...

Piper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)

Allogene Therapeutics (ALLO) announced preclinical data for ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy being evaluat...

Allogene Therapeutics presents data for ALLO-329 in autoimmune disease

JMP Securities analyst Reni Benjamin has maintained their neutral stance on ALLO stock, giving a Hold rating on November 11. Reni Benjamin's rating...

Cautious Hold Rating for Allogene Therapeutics Amid Promising Preclinical Data and Intense Competition

ALLO

MRNA

RNAC

Press Releases

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Management

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Health Care

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in November Investor Conferences

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Earnings

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Comments

Allogene Therapeutics

Allogene Therapeutics (ALLO) Opzioni

Allogene Therapeutics (NASDAQ:ALLO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO